Lv72
5000 积分 2023-04-01 加入
Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations
20天前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
1个月前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
1个月前
已完结
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
1个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
1个月前
已完结
Case Report: Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients with Lung Adenocarcinoma
1个月前
已完结
Germline Mutations as Risk Factors for Lung Cancer: A Systematic Review and Meta-analysis
2个月前
已完结
Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations
2个月前
已完结
Germline alterations in patients with lung cancer
2个月前
已完结
Ensartinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
3个月前
已完结
皖公网安备34019202002308
